Circulating Soluble Receptor for Advanced Glycation End Product Identifies Patients With Bicuspid Aortic Valve and Associated Aortopathies
Why the study?
Is elevated circulating sRAGE associated with bicuspid aortic valve and associated aortopathies?
Population
135 patients undergoing aortic valve replacement and/or ascending aortic replacement
Comparison
Measurement of circulating soluble receptor for… vs Patients with tricuspid aortic valve, or BAV…
Design
Cross-sectional
Authors
Discussion
Loading...
Member takes
Implication
Supports sRAGE as candidate biomarker for BAV aortopathy; hypothesis-generating and requires prospective validation before clinical use.
Structured PICO
Is elevated circulating sRAGE associated with bicuspid aortic valve and associated aortopathies?
P
Population
135 patients (bicuspid aortic valve [BAV], n=74; tricuspid aortic valve, n=61) undergoing aortic valve replacement (AVR) and/or ascending aortic replacement (AA)
I
Intervention
Measurement of circulating soluble receptor for advanced glycation end product (sRAGE)
C
Comparator
Patients with tricuspid aortic valve, or BAV patients undergoing AVR only
O
Outcome
Association of sRAGE levels with the presence of BAV and associated aortopathiessurrogate
Elevated circulating sRAGE is a potential biomarker for identifying bicuspid aortic valve and associated aortopathies independent of aortic diameter.
Cite This Study
Branchetti et al. (2014) studied this question.